Special Issue "Clinical Advances in Chronic Intestinal Diseases Treatment"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: 31 December 2021.
Interests: Gastroenterology; Gastrointestinal Disorders; Endocrinology; Intestinal transport; Serotonin
Over the past two decades, several advances have been made in the management of patients with chronic intestinal diseases from both evaluative and therapeutic perspectives. Among other chronic intestinal pathologies, irritable bowel syndrome (IBS), involving gut-brain axis alterations that causes abdominal pain, bloating, and alternating diarrhea and constipation, and inflammatory bowel disease (IBD), characterized by chronic inflammation of the gastrointestinal tract, are the best known and with the highest incidence and prevalence. Both chronic conditions, with significant overlap in terms of symptoms, pathophysiology, and treatment, need to be managed over long term and sometimes with overlay treatments.
However, new clinical approaches with novel mechanisms of action could offer new options for treatment of chronic intestinal diseases not optimally caracterized and controlled. Integration of novel approaches into clinical practice together with emerging strategies for management of chronic intestinal diseases will allow physicians to improve patient outcomes and potentially alter the progressive course of these diseases. Chronic intestinal diseases have a significant effect on the quality of life of affected patients and the increasing number of cases worldwide is a growing concern. Because of the overall burden of these diseases and its multifactorial etiology, efforts have been made to improve the medical management of these conditions.
This special issue aims to gather in one collection reviews and original contributions to illustrate the state of the art to provide novel approaches for the treatment of chronic intestinal diseases and the envisaged future in the management of these pathologies. On behalf of the Journal of Clinical Medicine you are cordially invited to contribute an article to the Special Issue “Clinical Advances in Chronic Intestinal Diseases Treatment”. Research articles, Reviews and Communications are welcome.
Dr. Jose E. Mesonero
Dr. Eva Latorre
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Functional Intestinal Disorders
- Inflammatory Bowel Disease
- Irritable Bowel Syndrome
- Crohn’s Disease
- Ulcerative Colitis
- Celiac Disease
- Gut-brain axis
- Alternative pharmacological treatments
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
1. Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management
2. Which is the first biologic we should choose in an IBD patient?